The coronavirus vaccine developed by Oxford University and AstraZeneca shows promise as it can generate b ...More

The coronavirus vaccine developed by Oxford University and AstraZeneca shows promise as it can generate both antibodies and cell-mediated immune responses, say several scientists in India and abroad, while cautioning that there is still a long way to go. ...Less

The regulator had issued a show cause notice to SII on Wednesday evening asking it to explain why trials ...More

The regulator had issued a show cause notice to SII on Wednesday evening asking it to explain why trials shouldn’t be suspended. SII had said earlier that it would be continuing with trials despite the global halt. ...Less

Pharma giant AstraZeneca on Saturday said that the clinical trials for their Oxford Covid vaccine have re ...More

Pharma giant AstraZeneca on Saturday said that the clinical trials for their Oxford Covid vaccine have resumed in the UK following confirmation by the Medicines Health Regulatory Authority that the trials were safe. ...Less

Regulatory endorsement is a welcome boost for AstraZeneca and the Oxford team, which have been accused of ...More

Regulatory endorsement is a welcome boost for AstraZeneca and the Oxford team, which have been accused of a lack of clarity about the results from late-stage trials.of the new variant but expect that their shots will be effective against it. ...Less

The vaccine, currently being evaluated by Britain's independent medicines regulator, provides "100 percen ...More

The vaccine, currently being evaluated by Britain's independent medicines regulator, provides "100 percent protection" against severe Covid disease requiring hospitalisation, Pascal Soriot said in an interview with the Sunday Times newspaper. ...Less

...More

...Less

The findings published in ‘Lancet' on Thursday based on 560 healthy adult volunteers shows that the ChAdO ...More

The findings published in ‘Lancet' on Thursday based on 560 healthy adult volunteers shows that the ChAdOx1 nCoV-19 vaccine is “safe and well-tolerated” with a lower reactogenicity profile in older adults than in younger adults, meaning the older age groups could build immunity to the disease. ...Less

It is believed that the two local candidates — which are in early stages of human trials — will enter the ...More

It is believed that the two local candidates — which are in early stages of human trials — will enter the market with a lag of a few weeks as compared to the Oxford candidate. ...Less

The Oxford University study found that a third dose of the vaccine increases antibody and T-cell immune r ...More

The Oxford University study found that a third dose of the vaccine increases antibody and T-cell immune responses, while the second dose can be delayed up to 45 weeks and also lead to an enhanced immune response. ...Less

The research, posted as a pre-print and yet to be peer-reviewed, estimated the effect of both the COVID-1 ...More

The research, posted as a pre-print and yet to be peer-reviewed, estimated the effect of both the COVID-19 vaccines on laboratory confirmed symptomatic disease in individuals aged 70 years or older in England. ...Less

The Drugs Controller General of India, Dr V G Somani, in his show-cause notice has asked SII as to why th ...More

The Drugs Controller General of India, Dr V G Somani, in his show-cause notice has asked SII as to why the permission granted for conducting phase 2 and 3 clinical trials of the vaccine candidate in the country be not suspended till patient safety is established. ...Less

"I would not imagine that either developers can submit for approval in all regulatory authorities at the ...More

"I would not imagine that either developers can submit for approval in all regulatory authorities at the same time, or that all regulatory authorities will take the same time for approval," Oxford's Andrew Pollard told lawmakers. ...Less

A day earlier, the Indian arm of US pharmaceutical giant Pfizer became the first to seek a similar approv ...More

A day earlier, the Indian arm of US pharmaceutical giant Pfizer became the first to seek a similar approval from India's drug regulator for its own COVID-19 vaccine in the country, after securing such clearance in the UK and Bahrain. ...Less

The Pune-based company is conducting phase-3 trials of the Oxford Covid-19 vaccine in India as part of in ...More

The Pune-based company is conducting phase-3 trials of the Oxford Covid-19 vaccine in India as part of international trials. ...Less

The Oxford Vaccine Group's director, Andrew Pollard, said in a media briefing there were "lots of cases" ...More

The Oxford Vaccine Group's director, Andrew Pollard, said in a media briefing there were "lots of cases" of infections in its Phase III trial in Britain, Brazil and South Africa. ...Less

The sources told that the Pune-based drug firm submitted its application to the DCGI on Friday seeking pe ...More

The sources told that the Pune-based drug firm submitted its application to the DCGI on Friday seeking permission for conducting the trials of 'Covidshield'. ...Less

The vaccine is "safe and effective", according to data published by The Lancet medical journal on Decembe ...More

The vaccine is "safe and effective", according to data published by The Lancet medical journal on December 8, with only one of the of the 23,754 volunteers who participated in the trials experiencing "possibly-related severe side effects". ...Less

"I'm optimistic that we could reach that point before the end of this year," chief trial investigator for ...More

"I'm optimistic that we could reach that point before the end of this year," chief trial investigator for the vaccine, Andrew Pollard said of presenting trial results this year. Asked if the vaccine would be ready by Christmas he said: "There is a small chance." ...Less

“India’s drug regulator is in touch with UK drug authorities on the approval progress of the AZ/Oxford va ...More

“India’s drug regulator is in touch with UK drug authorities on the approval progress of the AZ/Oxford vaccine trial,” Vinod Paul, head of the Vaccine Task Force Committee, said on December 12 at a meeting organised by Ficci. ...Less

In a statement Tuesday, the EU regulator said it has received a request for the vaccine to be green-light ...More

In a statement Tuesday, the EU regulator said it has received a request for the vaccine to be green-lighted under an expedited process and that it could be approved by Jan. 29 during an EMA meeting, "provided that the data submitted on the quality, safety and efficacy of the vaccine are sufficiently robust and complete." ...Less

The vaccine, which is being produced by bio-pharmaceutical giant AstraZeneca and also has a tie-up with t ...More

The vaccine, which is being produced by bio-pharmaceutical giant AstraZeneca and also has a tie-up with the Serum Institute of India, is being evaluated by the UK's independent Medicines and Healthcare products Regulatory Agency (MHRA) after the final cut of data was submitted by the government last Monday. ...Less

The observer-blind, randomised controlled study to determine the safety and immunogenicity of ''Covishiel ...More

The observer-blind, randomised controlled study to determine the safety and immunogenicity of ''Covishield'' on healthy Indian adults will begin at Bharati Vidyapeeth Medical College and Hospital in Pune. Serum Institute has partnered with British-Swedish pharma company for manufacturing the COVID-19 vaccine candidate, developed by the University of Oxford. ...Less